Investors & Media
News
Sage Therapeutics to Webcast R&D Day on December 13, 2016
The event will highlight Sage's R&D strategy, translational approaches and clinical development plans for SAGE-547 in super-refractory status epilepticus and postpartum depression, and for SAGE-217 in both mood and movement disorders.
In addition to presentations from members of the Sage management team, guest speakers include:
-
Eric Rosenthal , M.D., Associate Director, Neurosciences Intensive Care Unit; Director, Neurocritical Care Fellowship Program and Director, Critical Care Neuromonitoring atMassachusetts General Hospital -
Samantha Meltzer-Brody , M.D., M.P.H., Associate Professor; Associate Chair forFaculty Development ; and Director, Perinatal Psychiatry Program, University ofNorth Carolina Center for Women's Mood Disorders
A live webcast of the presentations can be accessed on the investor page
of Sage's website at investor.sagerx.com.
A replay of the webcast will also be archived for up to 30 days on
Sage's website following the conference. A scientific poster exhibit
will take place at
About
Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead compound, SAGE-547, is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder, and for postpartum depression. Sage is developing its next generation modulators, including SAGE-217 and SAGE-718, with a focus on acute and chronic CNS disorders.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161207005247/en/
Investor Contact:
paul.cox@sagerx.com
or
Media
Contact:
maureen.suda@sagerx.com
Source:
News Provided by Acquire Media